BioWorld MedTech

Feb. 26, 2016

Gloria Pharmaceuticals investing $40 million in Proteus Digital Health

HONG KONG — Harbin, China-based Gloria Pharmaceuticals Co Ltd plans to invest $40 million in U.S. digital medicine firm Proteus Digital Health Inc., of Redwood City, Calif., as part of its role in the firm's H round of financing. Read More

Better biomarkers needed to assess OA therapies, but patient voice still missing

Precision medicine 1M volunteer cohort becoming a reality

FDA prods Custom Ultrasonics to pull its reprocessing units

FDA's cancer moonshot aims at toppling the drug and device silos

Appointments & advancements

Products

Other News to Note

Daily M&A

Financings

MDD Diag Extra

Diabetes discovery may lead to stem cell-based therapies

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.